Cargando…

Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series

The coronavirus disease 2019 (COVID-19) pandemic remains one of the largest global health crises of the last century. Fortunately, COVID-19 vaccines have proven to be one of the most promising options in halting the progression of the pandemic. As more and more people receive COVID-19 vaccines, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekal, Sundeep, Husari, George, Okura, Marcel, Huang, Charity A, Bukari, Mohammed S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400017/
https://www.ncbi.nlm.nih.gov/pubmed/37546104
http://dx.doi.org/10.7759/cureus.41371
_version_ 1785084374378610688
author Bekal, Sundeep
Husari, George
Okura, Marcel
Huang, Charity A
Bukari, Mohammed S
author_facet Bekal, Sundeep
Husari, George
Okura, Marcel
Huang, Charity A
Bukari, Mohammed S
author_sort Bekal, Sundeep
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic remains one of the largest global health crises of the last century. Fortunately, COVID-19 vaccines have proven to be one of the most promising options in halting the progression of the pandemic. As more and more people receive COVID-19 vaccines, the medical community has learned a great deal about their efficacy and the occurrence of very rare adverse effects. While the number of thromboembolic events post-adenoviral vaccines has been well-documented in the medical literature, there has been limited information regarding thrombosis development after receiving a messenger RNA (mRNA)-based vaccine. This case series highlights four different patients who received an mRNA-based COVID-19 vaccine and subsequently developed venous thromboembolism. Therefore, we hope that after reviewing this article, physicians will be more aware of thrombosis-related developments following mRNA vaccine administration for COVID-19. Fortunately, with early diagnosis and prompt treatment, patients can still expect full recovery from any vaccine thrombosis-associated complications, and the benefits of receiving an mRNA-based COVID-19 vaccine still outweigh the risks of post-vaccination complications.
format Online
Article
Text
id pubmed-10400017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-104000172023-08-04 Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series Bekal, Sundeep Husari, George Okura, Marcel Huang, Charity A Bukari, Mohammed S Cureus Infectious Disease The coronavirus disease 2019 (COVID-19) pandemic remains one of the largest global health crises of the last century. Fortunately, COVID-19 vaccines have proven to be one of the most promising options in halting the progression of the pandemic. As more and more people receive COVID-19 vaccines, the medical community has learned a great deal about their efficacy and the occurrence of very rare adverse effects. While the number of thromboembolic events post-adenoviral vaccines has been well-documented in the medical literature, there has been limited information regarding thrombosis development after receiving a messenger RNA (mRNA)-based vaccine. This case series highlights four different patients who received an mRNA-based COVID-19 vaccine and subsequently developed venous thromboembolism. Therefore, we hope that after reviewing this article, physicians will be more aware of thrombosis-related developments following mRNA vaccine administration for COVID-19. Fortunately, with early diagnosis and prompt treatment, patients can still expect full recovery from any vaccine thrombosis-associated complications, and the benefits of receiving an mRNA-based COVID-19 vaccine still outweigh the risks of post-vaccination complications. Cureus 2023-07-04 /pmc/articles/PMC10400017/ /pubmed/37546104 http://dx.doi.org/10.7759/cureus.41371 Text en Copyright © 2023, Bekal et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Bekal, Sundeep
Husari, George
Okura, Marcel
Huang, Charity A
Bukari, Mohammed S
Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title_full Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title_fullStr Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title_full_unstemmed Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title_short Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
title_sort thrombosis development after mrna covid-19 vaccine administration: a case series
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400017/
https://www.ncbi.nlm.nih.gov/pubmed/37546104
http://dx.doi.org/10.7759/cureus.41371
work_keys_str_mv AT bekalsundeep thrombosisdevelopmentaftermrnacovid19vaccineadministrationacaseseries
AT husarigeorge thrombosisdevelopmentaftermrnacovid19vaccineadministrationacaseseries
AT okuramarcel thrombosisdevelopmentaftermrnacovid19vaccineadministrationacaseseries
AT huangcharitya thrombosisdevelopmentaftermrnacovid19vaccineadministrationacaseseries
AT bukarimohammeds thrombosisdevelopmentaftermrnacovid19vaccineadministrationacaseseries